Canada's Sunnybrook Health Sciences Centre Joins Elekta and Philips Research Consortium on MRI-Guided Radiation Therapy

Canada's Sunnybrook Health Sciences Centre Joins Elekta and Philips Research 
Consortium on MRI-Guided Radiation Therapy 
Research projects to have implications for cancer treatment worldwide 
TORONTO, May 10, 2013 /CNW/ - Elekta (NSE: EKTAb) and Royal Philips 
Electronics (NYSE: PHG, AEX: PHIA) announced today that Sunnybrook Health 
Sciences Centre (Toronto, Canada) will join their growing consortium to 
validate the clinical potential of MRI-guided radiation therapy. 
Sunnybrook Health Sciences Centre, the sixth largest cancer center in North 
America, is the fourth member to sign the research agreement to evaluate the 
new technology, which merges radiation therapy and magnetic resonance imaging 
(MRI) in a single system. Current clinical members of the group include the 
University Medical Center Utrecht, The University of Texas MD Anderson Cancer 
Center, and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital. 
Integrating an advanced 1.5 Tesla MRI machine with a sophisticated radiation 
therapy system will provide physicians with exceptional depictions of a 
patient's soft tissues and tumor and allow them to dynamically track their 
motion. This breakthrough innovation is designed to permit doctors to deliver 
radiation in real time under MR guidance for the most precise cancer 
treatments possible. 
"Sunnybrook Health Sciences Centre distinguishes itself in the world of 
science and medicine by its longstanding dedication of integrating research 
into clinical domain for the benefit of patients," says Tomas Puusepp, Elekta 
President and CEO. "With their international strength in the physical sciences 
– particularly in imaging technology – and its worldwide repute as a top 
flight cancer center, Sunnybrook is an ideal partner to help us advance this 
new technology." 
According to Michael Julius, Vice President, Research at Sunnybrook Health 
Sciences Centre, Sunnybrook's participation in the research consortium will 
bring a unique team of physicists, engineers and clinicians to focus on 
validating the advantages of MRI-guided radiation therapy through technology 
development and clinical trials. 
"We have identified a number of areas to study the value of this technology 
for patients," he says. "The ultimate goal – acquiring high resolution MRI 
images of pathology in real time as the radiation is being delivered – could 
have a dramatic impact on patient health and clinical outcomes." 
Today, the safety margin of normal tissue around the tumor absorbs a large 
portion of the radiation beam, adds Jean-Philippe Pignol, Professor of 
Radiation Oncology and a key leader on the Elekta partnership at Sunnybrook's 
Odette Cancer Centre. "The expectation is that MR-guided radiation therapy 
will enable us to treat more cancer tissue than normal tissue. In doing so, we 
could apply, in a single fraction, a huge dose to the tumor while avoiding 
side effects to normal tissues," he says. 
"The development of advanced imaging solutions for oncology therapy planning 
and delivery is a key focus area for Philips," says Gene Saragnese, CEO 
Imaging Systems at Philips Healthcare. "Philips is already closely working 
together with Sunnybrook Health Sciences Centre in this field, and we welcome 
their expertise to the research consortium for MR guided radiotherapy. The 
members will jointly work on the design and implementation of the clinical 
studies with the objective of bringing image-guided oncology therapy to the 
next level, and ultimately creating the future of healthcare." 
The integrated MRI-guided radiation therapy system is in development and not 
available for sale. 
For further information, please contact:  Johan Andersson, Director, Investor 
Relations, Elekta AB  Tel: +46 702 100 451, email: 
Time zone: CET: Central European Time 
Michelle Joiner, Director, Global Public Relations and Brand Management, 
Elekta   Tel: +1 770-670-2447, email: Time zone: 
ET: Eastern Time 
Steve Klink, Philips Corporate Communications  Tel: +31 20 5977415, email: 
About Elekta  Elekta is a human care company pioneering significant 
innovations and clinical solutions for treating cancer and brain disorders. 
The company develops sophisticated, state-of-the-art tools and treatment 
planning systems for radiation therapy, radiosurgery and brachytherapy, as 
well as workflow enhancing software systems across the spectrum of cancer 
care. Stretching the boundaries of science and technology, providing 
intelligent and resource-efficient solutions that offer confidence to both 
healthcare providers and patients, Elekta aims to improve, prolong and even 
save patient lives. 
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 
hospitals worldwide. Elekta employs around 3,400 employees globally. The 
corporate headquarters is located in Stockholm, Sweden, and the company is 
listed on the Nordic Exchange under the ticker EKTAb. Website: 
About Royal Philips Electronics  Royal Philips Electronics (NYSE: PHG, AEX: 
PHIA) is a diversified health and well-being company, focused on improving 
people's lives through meaningful innovation in the areas of Healthcare, 
Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips 
posted 2012 sales of EUR 24.8 billion and employs approximately 116,000 
employees with sales and services in more than 100 countries. The company is a 
leader in cardiac care, acute care and home healthcare, energy efficient 
lighting solutions and new lighting applications, as well as male shaving and 
grooming and oral healthcare. News from Philips is located at 
SOURCE: Elekta 
To view this news release in HTML formatting, please use the following URL: 
CO: Sunnybrook Health Sciences Centre
-0- May/10/2013 13:13 GMT
Press spacebar to pause and continue. Press esc to stop.